Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT03239561
- Locations
- 🇺🇸
Invicro, New Haven, Connecticut, United States
A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT03235219
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸ProSciento, Inc., Chula Vista, California, United States
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 213
- Registration Number
- NCT03234972
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Peking Union Medical College Hospital, Beijing, China
🇨🇳Peking University People s Hospital, Beijing, China
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 287
- Registration Number
- NCT03227224
- Locations
- 🇫🇷
Hopital Sainte Anne, Paris, France
🇷🇺City Clinical Psychiatric Hopsital 3, Moscow, Russian Federation
🇺🇸Clinical NeuroScience Solutions Inc, Orlando, Florida, United States
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT03217812
- Locations
- 🇭🇰
Queen Mary Hospital University of Hong Kong, Hong Kong, Hong Kong
🇰🇷Ulsan University Hospital, Ulsan, Korea, Republic of
🇲🇾Hospital Ampang, Ampang, Malaysia
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
- Conditions
- Amyloidosis
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 416
- Registration Number
- NCT03201965
- Locations
- 🇫🇷
CHU De Poitiers, Poitiers, France
🇫🇷Institut Paoli Calmettes, Marseille, France
🇫🇷Chu Hotel Dieu, Nantes cedex 01, France
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 147
- Registration Number
- NCT03185819
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
🇮🇹OSP RIUNITI-DIP Donna- Bambino, Foggia, Italy
🇭🇺Vadaskert Gyermek es Ifjusagpszichiatriai Korhaz es Szakambulancia, Budapest, Hungary
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-64140284 150 mgDrug: JNJ-64140284 10 mgDrug: JNJ-64140284 0.5 mgDrug: JNJ-64140284 50 mgDrug: JNJ-64140284 (dose to be determined [TBD])Drug: JNJ-64140284 0.1 mgDrug: JNJ-64140284 2.5 mgDrug: Placebo
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT03180762
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 171
- Registration Number
- NCT03170518
- Locations
- 🇺🇸
Buckeye Health and Research, LLC, Columbus, Ohio, United States
🇺🇸Sante Clinical Research, Kerrville, Texas, United States
🇧🇷Hospital e Maternidade Dr Christovao da Gama S.A, Santo Andre, Brazil
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 383
- Registration Number
- NCT03162796
- Locations
- 🇵🇱
Centrum Medyczne Hetmańska, Poznań, Poland
🇵🇱Etyka Osrodek Badan Klinicznych, Olsztyn, Poland
🇵🇱Nasz Lekarz Przychodnie Medyczne, Torun, Poland